Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

被引：1
|
作者：
Mehta, Pallavi [1 ]
Yadav, Neha [1 ]
Bhaarat, Mohan [2 ]
Mirgh, Sumeet Prakash [3 ]
Khushoo, Vishvdeep [3 ]
Thekuddan, Shinto Francis [1 ]
Agrawal, Narendra [3 ]
Ahmed, Rayaz [4 ]
Bhurani, Dinesh [3 ]
机构：
[1] Rajiv Gandhi Canc Inst & Res Ctr, Dept Hematooncol, New Delhi, India
[2] Rajiv Gandhi Canc Inst, New Delhi, India
[3] Rajiv Gandhi Canc Inst & Res Ctr, Dept Hematooncol & BMT, New Delhi, India
[4] Rajiv Gandhi Canc Inst & Res Inst, New Delhi, India
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131674
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5572
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Retrospective Study of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients in a Tertiary Care Hospital in India
    Pallavi Mehta
    Neha Yadav
    Bhaarat Folbs
    Jyotsna Kapoor
    Vishvdeep Khushoo
    Narendra Agrawal
    Rayaz Ahmed
    Dinesh Bhurani
    Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 264 - 273
  • [2] Retrospective Study of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients in a Tertiary Care Hospital in India
    Mehta, Pallavi
    Yadav, Neha
    Folbs, Bhaarat
    Kapoor, Jyotsna
    Khushoo, Vishvdeep
    Agrawal, Narendra
    Ahmed, Rayaz
    Bhurani, Dinesh
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (02) : 264 - 273
  • [3] Efficacy and Safety of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed and/or Refractory Multiple Myeloma: Pooled Analysis of 2 Single Arm Studies
    Jakubowiak, Andrzej
    Jasielec, Jagoda
    Rosenbaum, Cara
    Orlowski, Robert Z.
    Cohen, Adam
    Bensinger, William I.
    Anderson, Aparna
    Dossett, Tommy
    Iskander, Karim
    Mezzi, Khalid
    Welliver, Timothy
    Yusuf, Akeem
    Durie, Brian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E34 - E34
  • [4] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
    Shah, Jatin J.
    Stadtmauer, Edward A.
    Abonour, Rafat
    Cohen, Adam D.
    Bensinger, William I.
    Gasparetto, Cristina
    Kaufman, Jonathan L.
    Lentzsch, Suzanne
    Vogl, Dan T.
    Gomes, Christina L.
    Pascucci, Natalia
    Smith, David D.
    Orlowski, Robert Z.
    Durie, Brian G. M.
    BLOOD, 2015, 126 (20) : 2284 - 2290
  • [5] A PHASE 1-2 STUDY OF CARFILZOMIB-POMALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE
    Bringhen, S.
    Mina, R.
    Liberati, A. M.
    Belotti, A.
    Gaidano, G.
    Bertazzoni, P.
    Stocchi, R.
    Ruggeri, M.
    Ribolla, R.
    Di Sano, C.
    Patriarca, F.
    Bernardini, A.
    De Paoli, L.
    Cafro, A. M.
    Palumbo, A.
    Sonneveld, P.
    Boccadoro, M.
    HAEMATOLOGICA, 2017, 102 : 25 - 25
  • [6] Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
    Shah, Jatin
    Usmani, Saad
    Stadtmauer, Edward A.
    Rifkin, Robert M.
    Berenson, James R.
    Berdeja, Jesus G.
    Lyons, Roger M.
    Klippel, Zandra
    Chang, Yu-Lin
    Niesvizky, Ruben
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (09): : 570 - +
  • [7] Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial
    Sonneveld, Pieter
    Zweegman, Sonja
    Cavo, Michele
    Nasserinejad, Kazem
    Troia, Rosella
    Pour, Ludek
    Croockewit, Sandra
    Corradini, Paolo
    Patriarca, Francesca
    Wu, Kalung
    Droogendijk, Jolanda
    Broyl, Annemiek
    Minnema, Monique C.
    Costa, Bruno
    Iskander, Karim Saad
    Boccadoro, Mario
    BLOOD, 2018, 132
  • [8] Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study.
    Rosenbaum, Cara Ann
    Stephens, Leonor Ano
    Kukreti, Vishal
    Zonder, Jeffrey A.
    Cole, Craig
    Zimmerman, Todd M.
    Reece, Donna Ellen
    Berdeja, Jesus G.
    Severson, Erica
    Revethis, Andrea
    Wolfe, Brittany
    McDonnell, Kathryn
    Nam, Jennifer
    Griffith, Kent A.
    Jakubowiak, Andrzej J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum
    Matsumura-Kimoto, Yayoi
    Kuroda, Junya
    Kaneko, Hitomi
    Kamitsuji, Yuri
    Fuchida, Shin-ichi
    Nakaya, Aya
    Shibayama, Hirohiko
    Uoshima, Nobuhiko
    Yokota, Isao
    Uchiyama, Hitoji
    Yagi, Hideo
    Kosugi, Satoru
    Matsui, Toshimitsu
    Ishikawa, Jun
    Matsuda, Mitsuhiro
    Ohta, Kensuke
    Iida, Masato
    Tanaka, Hirokazu
    Kobayashi, Masayuki
    Wada, Katsuya
    Shimazaki, Chihiro
    Nomura, Shosaku
    Imada, Kazunori
    Hino, Masayuki
    Matsumura, Itaru
    Kanakura, Yuzuru
    Takaori-Kondo, Akifumi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (05) : 541 - 550
  • [10] phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Sperling, Adam
    Bianchi, Giada
    Munshi, Nikhil
    O'Donnell, Elizabeth
    Branagan, Andrew
    Avigan, David
    Liegel, Jessica
    Harrington, Cynthia
    Agyemang, Emerentia
    Lively, Kathleen
    Packer, Lisette
    Han, Samuel
    Minsky, Cole
    Riadi, Manal
    Mcvey, Cailin
    Donnelly, Kaleigh
    Smith, Caitlin
    Katzeff, Mackenna
    Goguen, Amy
    Horick, Nora
    Richardson, Paul
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S220 - S221
12345